Published in Future Microbiol on January 01, 2010
Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines. Exp Mol Med (2014) 0.85
Felid herpesvirus type 1 infection in cats: a natural host model for alphaherpesvirus pathogenesis. ISRN Vet Sci (2012) 0.81
Herpes simplex virus 1 infection on a reconstructive free flap. Eplasty (2013) 0.79
Pathogen recognition and innate immunity. Cell (2006) 44.14
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA (2006) 7.46
Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med (2002) 6.23
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis (2002) 5.09
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev (2009) 4.55
Herpes simplex virus infections. Lancet (2001) 4.41
The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health (2004) 3.95
Genital herpes. Lancet (2007) 3.83
Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A (2004) 3.74
An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ (2008) 3.62
Herpes simplex virus epidemiology and ocular importance. Cornea (2001) 3.14
Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis (2008) 2.78
HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology (2009) 2.02
Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. J Immunol (2002) 1.88
Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology (2004) 1.87
The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection. Sex Transm Infect (2006) 1.56
A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect (2005) 1.54
Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am J Reprod Immunol (2008) 1.49
Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis (2005) 1.49
Toll-like receptors, innate immunity and HSV pathogenesis. Herpes (2006) 1.48
Toll-like receptors and corneal innate immunity. Curr Mol Med (2006) 1.44
Characterization of Toll-like receptors in the female reproductive tract in humans. Hum Reprod (2005) 1.42
Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr (2004) 1.42
Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol (2008) 1.41
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis (2007) 1.37
Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis (2004) 1.36
Differential expression of Toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Infect Immun (2004) 1.36
Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes (2004) 1.35
Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect (2007) 1.32
Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread. J Virol (2001) 1.31
TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest (2008) 1.28
The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect (2008) 1.23
Host defense peptides in the oral cavity and the lung: similarities and differences. J Dent Res (2008) 1.19
Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol (2002) 1.19
Toll-like receptors at the ocular surface. Ocul Surf (2008) 1.18
Microbial compounds induce the expression of pro-inflammatory cytokines, chemokines and human beta-defensin-2 in vaginal epithelial cells. Microbes Infect (2005) 1.17
Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J Virol (2006) 1.16
New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res (1999) 1.14
Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect (2009) 1.12
Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol (2006) 1.08
New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines (2009) 1.07
Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2. J Immunol (2003) 1.04
Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J Virol (2006) 1.04
Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis (2002) 1.04
Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women. Antiviral Res (2008) 1.02
Neuronal propagation of HSV1 from the oral mucosa to the eye. Invest Ophthalmol Vis Sci (2000) 0.99
The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am J Reprod Immunol (2008) 0.98
Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs (2008) 0.98
Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol (2003) 0.98
Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin Immunol (1997) 0.95
Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul Surf (2006) 0.95
A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva. Invest Ophthalmol Vis Sci (2009) 0.94
The Toll of herpes simplex virus infection. Trends Microbiol (2004) 0.94
The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes (2002) 0.89
Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs. Vaccine (1995) 0.88
FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J (2009) 0.86
The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches. BMC Infect Dis (2001) 0.85
Immunostimulatory CpG treatment for genital HSV-2 infections. J Antimicrob Chemother (2003) 0.84
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis (2006) 0.84
Expression of toll-like receptors in the healthy and herpes simplex virus-infected cornea. Cornea (2007) 0.83
Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis (1986) 0.82
Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int Immunopharmacol (2002) 0.81
The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. J Clin Virol (2004) 0.79
An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents (2008) 0.78
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem (2005) 1.54
Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am J Reprod Immunol (2008) 1.49
Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res (2005) 1.45
CD1d degradation in Chlamydia trachomatis-infected epithelial cells is the result of both cellular and chlamydial proteasomal activity. J Biol Chem (2007) 1.30
Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. J Clin Microbiol (2011) 1.30
Mycoplasma genitalium-encoded MG309 activates NF-kappaB via Toll-like receptors 2 and 6 to elicit proinflammatory cytokine secretion from human genital epithelial cells. Infect Immun (2008) 1.22
Intracellular Mycoplasma genitalium infection of human vaginal and cervical epithelial cells elicits distinct patterns of inflammatory cytokine secretion and provides a possible survival niche against macrophage-mediated killing. BMC Microbiol (2009) 1.21
Mycoplasma genitalium rapidly disseminates to the upper reproductive tracts and knees of female mice following vaginal inoculation. Infect Immun (2009) 1.09
Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis (2005) 1.08
Role of primary human alveolar epithelial cells in host defense against Francisella tularensis infection. Infect Immun (2007) 1.08
Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology (2008) 1.07
Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J Virol (2006) 1.04
Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. PLoS One (2012) 1.01
Innate immune mediator profiles and their regulation in a novel polarized immortalized epithelial cell model derived from human endocervix. J Reprod Immunol (2011) 0.99
A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine (2012) 0.93
Viral load and acute otitis media development after human metapneumovirus upper respiratory tract infection. Pediatr Infect Dis J (2012) 0.92
Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol (2002) 0.90
High-throughput multistrain polymerase chain reaction quantification of Chlamydia trachomatis from clinical and preclinical urogenital specimens. Diagn Microbiol Infect Dis (2009) 0.87
FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J (2009) 0.86
Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One (2013) 0.85
Immunostimulatory CpG treatment for genital HSV-2 infections. J Antimicrob Chemother (2003) 0.84
Determining Persistence of Bocavirus DNA in the Respiratory Tract of Children by Pyrosequencing. Pediatr Infect Dis J (2016) 0.78
Quantification of bacterial uropathogens in preclinical samples using real-time PCR assays. Curr Microbiol (2013) 0.78
An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents (2008) 0.78
Development and utilization of a custom PCR array workflow: analysis of gene expression in mycoplasma genitalium and guinea pig (Cavia porcellus). Mol Biotechnol (2015) 0.78
Association between body mass index, sexually transmitted infections, and contraceptive compliance. J Womens Health (Larchmt) (2013) 0.77
Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis. Mol Med (2013) 0.76
Correction: Intraluminal Flagellin Differentially Contributes to Gut Dysbiosis and Systemic Inflammation following Burn Injury. PLoS One (2017) 0.75